ClinicalTrials.gg
RecruitingNCT06129591Updated Nov 18, 2026

Topical CBD Scar Healing Study

A Phase 1 interventional study of Vantage Hemp CBD Isolate + Silicone patch and Silicone patch in Paramedian Forehead Flap, sponsored by University of Oklahoma. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Oklahoma · Phase 1, Interventional, and Treatment

Updated Nov 18, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to find out what effects (good and bad) that cannabidiol (CBD) has on scar healing and appearance in patients who have undergone paramedian forehead flap reconstruction.

Read the detailed description

The patient will be asked to apply a silicone patch to half of the scar and experimental ointment (CBD oil ointment) with silicone patch) to the other half of the scar on their forehead. They will be randomized to which half of the scar the ointment will be applied. Neither they nor their physician will choose which half of the scar will have the experimental ointment applied. Specific instructions will be given to the patient on how to apply each drug (the silicone patch to one segment of the scar and the CBD with silicone patch to the other segment of the scar). They will apply the treatments twice a day for 2 months and, at their follow-up appointments, complete two questionnaires about how the scar is healing. Photographs of the scars will be taken at each visit and will be evaluated to determine if there is an improved outcome in the appearance of the scar.

02

Conditions studied

  • Paramedian Forehead Flap

Keywords

  • CBD oil
  • Paramedian Forehead Flap Reconstruction
  • silicone patch
03

In context

Lead sponsor

University of Oklahoma is the lead sponsor of 432 studies on the registry; 98 are open to participants now.

Of its 42 completed or terminated interventional studies of FDA-regulated products, 16 (38%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients that are adults (18+) of all genders and ethnicities who have undergone a PMFF (Paramedian forehead flap) will be considered for this study.
  • English-speaking patients

Exclusion criteria

Exclusion Criteria

  • Patients younger than 18 years of age
  • Non-English speaking patients
  • Patients with known allergies to CBD
  • Pregnant women
  • Prisoners
  • Patients with moderate to severe hepatic impairment
  • A history of suicidal ideation and behavior within the last 6 months
  • Patients with severe depression
  • Who anticipate coadministration of other CNS depressants including alcohol that could potentiate the sedating effects of the drug
  • Patients with a history of severe reactions to adhesives
  • Patients who anticipate coadministration of potentially hepatotoxic drugs
  • Patients who anticipate coadministration of sensitive CYP2C19 substrates per labeling

Termination criteria

  • There will be immediate termination from the study if any allergic response to the CBD/silicone combination occurs or if the topical application of CBD/silicone significantly worsens the scar outcome at the Follow Up 2 visit or at any subsequent visit.
  • Subject will not receive any additional CBD doses if they experience an adverse event assessed as ≥ Grade 3 (including hepatotoxicities and hematologic adverse events, ≥ Grade 2 for the system-organ class of Cardiac Disorders) according to v5. They will remain on study in follow-up until the adverse event resolves or stabilizes.
  • If the patient voluntarily requests cessation in the study.
  • Pregnancy
  • Increase in serum transaminases (/AST) to above three times the or increase in total to above two times the upper limit of normal.
  • If a subject experiences worsening depression or suicidal ideation or behavior, the participant will be discontinued from treatment with CBD and immediately referred to a mental health professional. The decision to resume treatment with CBD will be made in collaboration with a mental health professional.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    Split-scar randomized trial arm with CBD oil

    The study targets the vertical forehead scar, treating half with CBD oil and a silicone patch (experimental).

    Drug: Vantage Hemp CBD Isolate + Silicone patch

  • Placebo comparator
    Split-scar randomized trial arm without CBD oil

    The study targets the vertical forehead scar, treating the other scar half with a silicone patch (control).

    Drug: Silicone patch

Interventions

  • DrugVantage Hemp CBD Isolate + Silicone patch

    The study intervention is prospective in nature. This "split scar" study directly compares two parts of the healing scar during clinic visits. Photos will be taken at each visit to track progress. Assessments will be done over a period of around 7 months using the Modified Patient and Observer Scar Assessment Scale, followed by blinded photo evaluations using the Scar Cosmesis and Rating Scale.

  • DrugSilicone patch

    Standard of care silicone patch will be used as the control part of the split scar study. This "split scar" study directly compares two parts of the healing scar during clinic visits. Photos will be taken at each visit to track progress. Assessments will be done over a period of around 7 months using the Modified Patient and Observer Scar Assessment Scale, followed by blinded photo evaluations using the Scar Cosmesis and Rating Scale.

06

What researchers measure

Primary outcomes

  1. Assessment of subjective and objective effects of CBD on the outcomes of healing scars.

    Proportion of patients who have a positive effect using CBD oil in combination with the silicone patch. This will be assessed using the Scar Cosmesis Assessment and Rating (SCAR) scale to determine the impact of CBD oil and silicon patch combo. This photographic evaluation of scare will be done over a period of around 7 months to evaluate the scar outcomes, using the scoring system with minimum score of 0 (being best possible outcome) and maximum score of 13 (worst possible scar outcome).

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
    Recruiting
    • Mark Mims, M.D., Ph.D., · ContactMark-Mims@ouhsc.edu · 405-271-5504
    • Mark Mims, M.D., Ph.D., · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for Jul 2027, 7 months later.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2023
First posted
Nov 13, 2023
StartEst.
Dec 2026was Sep 2026
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Dec 2026
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Start date Sep 2026→Dec 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06129591
Responsible party
Sponsor
First posted
Nov 13, 2023
Start date
Dec 2026 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Jul 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Ingrid Block
Contact
SCC-IIT-Office@ouhsc.edu
405-271-8777
Lead Nurse
Contact
SCC-IIT-Office@ouhsc.edu
405-271-8777
Mark Mims, M.D., Ph.D.
principal investigator · University of Oklahoma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion